Skip to main content

Table 3 Overview of demographic and clinical information collected

From: Cohort profile: King’s Health Partners bladder cancer biobank

Basics Sample size 997
Patients consented 531
Number of variables 21
Involvement in clinical trial Yes, No
Demographics Age  
Gender Male, Female
Inclusion in Clinical Trial Yes, No
Comorbidities Hypertension, Diabetes, Other cancer, Hypercholesterolaemia, Respiratory disease, Cardiovascular disease, Chronic Kidney Disease, Psychiatric Disorder
Smoking Yes, No, Unknown
Bladder cancer characteristics Diagnosis New, Recurrent
Histology Urothelial Cell Carcinoma, Papillary Urothelial Cell Carcinoma, Squamous Cell Carcinoma, Adenocarcinoma, Micropapillary variant, Plasmacytoid variant, Paraganglioma, Papilloma, Small cell carcinoma, Sarcomatoid, Unknown
Grade G1, G2, G3
TNM stage  
Lymphovascular invasion Yes, No
Surgery Cystoprostatectomy, Cystectomy, Nephrouretectomy, Uretectomy, Nephrouretectomy and cystoprostatectomy, Cystectomy and ureterectomy, Diverticulectomy, Nephrouretectomy and cystectomy, Nephrouretectomy and partial cystectomy, Ureterostomy, Urethrectomy, Exenteration, None
Chemotherapy Neoadjuvant, Adjuvant, Chemotherapy, Palliative, Neoadjuvant and adjuvant, None
Radiotherapy Yes, No
Intravesical therapy Di Stasi, BCG, Mitomycin, BCG and mitomycin in different occasions, Di Stasi and mitomycin in different occasions, Other, None
Intravesical therapy failure Yes, No
Laser ablation Yes, No
Immunotherapy Yes, Poorly tolerated, Unknown, No, Not Applicable